Choosing the best length of oxaliplatin after stomach surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed stomach or stomach–esophagus junction adenocarcinoma and had curative surgery (D1 beta or D2 resection)
- Your cancer is stage II or III (per the AJCC 8th edition staging system)
- You are age 19 or older and can do daily activities fairly well (ECOG 0 to 2)
- You have enough bone marrow, kidney, and liver function based on blood tests
- You can understand and sign the informed consent form
- You have no spread to other organs (no metastasis), and you are not currently recovering from serious post-surgery complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
This trial compares two lengths of an oral chemotherapy medicine (9 months vs 1 year) after surgery for stage II stomach cancer. It aims to see which schedule works better and is easier to complete, while checking safety for people without major health problems.
This trial tests whether adding heated chemotherapy to the belly right after surgery can help people with stomach cancer live longer. It is done during the same operation, aiming to kill any remaining cancer cells.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.